Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S

Core Viewpoint - BioPorto A/S has successfully completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million, which will enhance the company's financial flexibility to pursue strategic priorities and strengthen its commercial platform [1][2]. Group 1: Private Placement Details - The private placement involved 40,438,426 new shares and is expected to generate gross proceeds of around DKK 43 million [1][2]. - The subscription price for the new shares is scheduled to be paid by 24 November 2025, with the share capital increase registration to follow shortly thereafter [2]. - BioPorto anticipates that the new shares will be listed on Nasdaq Copenhagen A/S by no later than 26 November 2025 [2]. Group 2: Strategic Implications - The funds raised will support the completion of data collection, submission of a pre-submission to the FDA, and initiation of a Validation Study in the U.S. clinical trial [2]. - The Board of BioPorto has considered various future financing options, including potential divestments of non-core assets and credit facilities, to ensure a balanced funding structure [2]. - The company aims to position itself for positive cash flow by the second half of 2027 [2]. Group 3: Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management and outcomes [4][5]. - The flagship products are based on the NGAL biomarker, which aids in the risk assessment and management of Acute Kidney Injury (AKI) [5]. - BioPorto's tests are marketed under various registrations, including CE mark and FDA clearance for ProNephro AKI™ in the U.S. [5].